Description: DGX's strong YTD gains and momentum in advanced diagnostics and acquisitions highlight why it may stand out in the competitive testing market against HOLX.

Description: At the recent RSNA conference in Chicago, Hologic presented new studies on its AI-powered 3DQuorum and Genius AI Detection technologies, showing that these solutions can streamline radiologists’ workflows and maintain cancer detection quality. These advancements are especially relevant as they address radiologist shortages and could improve efficiency without sacrificing diagnostic accuracy. We'll examine how Hologic’s push into AI-driven imaging could impact its investment narrative and...

Description: HOLX is set to present new real-world data at RSNA 2025, showing how its AI-driven breast imaging tools boost workflow without sacrificing detection.

Description: The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead

Description: MARLBOROUGH, Mass., November 25, 2025--New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA

Description: Pre-Market Stock Futures: The futures are trading higher as we get ready to close out a volatility-filled week that saw a massive roller coaster ride on Thursday after NVIDIA Corp. (NASDAQ: NVDA) earnings ignited a rally on the open that reversed at midday and finished the day deep in the red. Wall Street pundits cited ... Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More

Description: HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.

Description: Hologic’s consensus analyst price target has nudged upward, rising from $75.08 to $76.17 per share. This change comes amid increased attention following news of a proposed acquisition. The slight boost reflects a mix of optimism regarding the deal's valuation and ongoing uncertainty about the company’s growth prospects. Read on to find out how these evolving dynamics may influence Hologic’s stock narrative and what steps you can take to stay informed as the story develops. Analyst Price...

Description: US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...

Description: HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.

Description: Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: The HPV testing and Pap test market is set to grow from USD 2.44 billion in 2025 to USD 3.94 billion by 2030, with a CAGR of 10.0%. This growth is fueled by increased awareness of cervical cancer and government-led screening initiatives. Consumables lead the market, driven by demand for reagents and collection kits essential for testing. While cervical cancer screening dominates, vaginal cancer screening is poised for rapid growth, aided by enhanced diagnostic capabilities. The Asia Pacific regi

Description: VolitionRX Ltd (VNRX) reports a 32% revenue increase and strategic agreements, while navigating market unpredictability and capital challenges.

Description: Hologic (HOLX) shares have edged slightly lower recently, moving down by about 0.4%. Despite this dip, the company’s performance over the past month has been positive, with stock returns climbing 13%. See our latest analysis for Hologic. Hologic’s stock has shown some encouraging momentum, with a 12.65% 1-month share price return standing out against a softer backdrop of longer-term performance. While its 1-year total shareholder return is down 4.2%, the recent rebound suggests investors are...

Description: VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025. Volition management will host a conference call tomorrow, November 14 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Description: HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.

Description: MARLBOROUGH, Mass., November 12, 2025--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking

Description: Ivor Campbell, CEO of medtech recruitment consultancy Snedden Campbell, reflects on what companies in the UK and Europe can do to compete for investment against the US.

Description: The Biopsy Devices market is projected to reach $4.02 billion by 2033, growing from $2.43 billion in 2024 at a CAGR of 5.75%. This growth is driven by personalized care demand, rising cancer cases, and minimally invasive treatments enhancing patient comfort. Key biopsy devices include needle, punch, and surgical tools for various medical needs. Advancements in biopsy technology ensure precise, early cancer detection and improved patient outcomes. Leading companies like Cardinal Health, Hologic,

Description: Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.

Description: Hologic (HOLX) reported a net profit margin of 13.8%, down from 19.6% in the previous year, with EPS declines averaging 26.7% per year over the last five years. The company’s most recent performance was affected by a one-off $277.8 million loss, while revenue is forecast to grow at 4.7% per year, notably slower than the US market’s 10.5% average. With the current share price at $74.11, trading below the estimated fair value of $105.96, investors are now weighing whether margin trends and the...

Description: Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.

Description: Medical technology company Hologic (NASDAQ:HOLX) announced better-than-expected revenue in Q3 CY2025, with sales up 6.2% year on year to $1.05 billion. Its non-GAAP profit of $1.13 per share was 2.7% above analysts’ consensus estimates.

Description: MARLBOROUGH, Mass. AP) — Hologic Inc. HOLX) on Monday reported fiscal fourth-quarter earnings of $187.3 million.

Description: MARLBOROUGH, Mass., November 03, 2025--Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

Description: The X-ray system market is poised for growth due to technological advances in imaging, increasing healthcare expenditure, and rising chronic disease cases. Key opportunities lie in the adoption of digital radiography and computed tomography, with key players like Siemens and GE Healthcare at the forefront of innovation. X-Ray System Market X-Ray System Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "X-Ray System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2025-

Description: The mammography devices market offers growth opportunities through advancements in digital and 3D technology, heightened breast cancer awareness, and supportive government policies for regular screenings. These factors drive increased demand for mammography systems worldwide, particularly in emerging markets. Mammography Devices Market Mammography Devices Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Mammography Devices Market - Global Industry Size, Share, Growth, Trends, Opportunity, a

Description: Wondering if Hologic could be a hidden value opportunity or just another stock to watch from the sidelines? Here is what you need to know before making up your mind. Shares have seen an 8.3% increase over the last month, but remain down 10.2% over the past year. The market appears to be weighing fresh growth optimism against lingering risks. Recent headlines highlight Hologic’s strategic moves in women’s health technology, with new product launches and several innovative partnerships drawing...

Description: Medical technology company Hologic (NASDAQ:HOLX) will be reporting results this Monday afternoon. Here’s what to expect.

Description: Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: Med-tech veteran Robert Kline has joined the Board of Directors at PainTEQ, a strategic move to capitalize on his commercialization and growth expertise as the company redefines interventional spine care.

Description: Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls

Description: Check out the companies making headlines yesterday:

Description: The transaction is anticipated to conclude in the first half of 2026, pending approval from Hologic shareholders.

Description: Hologic's fair value estimate has edged higher following recent acquisition news, with analysts increasing their price targets in response to strong quarterly results and a raised full-year outlook. The discount rate has also nudged down slightly, which reflects a modest reduction in perceived risk. Stay tuned to discover how you can stay ahead of evolving developments in Hologic's investment story. What Wall Street Has Been Saying Following news of Hologic’s acquisition by funds managed by...

Description: Find insight on Blackstone and TPG’s acquisition of Hologic and more in the latest Market Talks covering Financial Services.

Description: Hologic agreed Tuesday to be acquired by Blackstone and TPG in a deal that values the women's health tech company at up to $18.3 billion.

Description: Financial stocks were mixed in late Tuesday afternoon trading, with the NYSE Financial Index easing

Description: Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index climbing 0.1% and th

Description: Financial stocks were mixed in Tuesday afternoon trading with the NYSE Financial Index little change

Description: Shares of medical technology company Hologic (NASDAQ:HOLX) jumped 3.1% in the afternoon session after the company announced it agreed to be acquired by private equity firms Blackstone and TPG in a deal that takes the company private.

Description: Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.2% and the Health Ca

Description: Citigroup (C), Barclays (BCS), and Bank of America (BAC) are arranging $12.25 billion in debt to bac

Description: The Dow Jones and the S&P 500 were up, while the Nasdaq Composite was flat in late-morning trading T

Description: HOLX vs. IDXX: Which Stock Is the Better Value Option?

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Galaxy Digital (GLXY.TO, GLXY) topping third quarter earnings estimates, Halliburton (HAL) seeing a massive drop in its net income, and Blackstone (BX) and TPG Inc. (TPG) agreeing to take Hologic (HOLX) private in a deal worth $18.3 billion. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Private equity firms Blackstone and TPG will spend more than $13 billion to buy women’s health specialist Hologic. The companies said Tuesday they will pay up to $79 for each Hologic share in a deal that takes the company private. Shares of Hologic rose after markets opened Tuesday.

Description: Under the terms of the deal, Blackstone and TPG agreed to acquire all outstanding shares of the women’s-health company for $76 apiece in cash.

Description: MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas, October 21, 2025--Hologic to be Acquired by Blackstone and TPG for up to $79 per Share

Description: Funds managed by Blackstone and TPG plan to acquire the medtech firm for up to $79 per share.

Description: A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Description: Financial stocks were advancing in late Monday trading, with the NYSE Financial Index adding 1.1% an

Description: Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S

Description: Financial stocks were advancing in late Monday afternoon trading, with the NYSE Financial Index up 1

Description: Hologic stock climbed Monday on a report that Blackstone and TPG were in advanced talks to acquire the medical device maker. The deal values Hologic at more than $17 billion including debt, Bloomberg reported, citing people familiar with the matter. TPG declined to comment in an email to Barron’s. Hologic and Blackstone didn’t respond to requests for comment.

Description: Shares of global alternative asset manager TPG (NASDAQ:TPG) jumped 2.3% in the morning session after reports surfaced that the private equity firm, along with Blackstone, was in advanced negotiations to acquire medical device maker Hologic. The potential take-private deal valued Hologic at more than $17 billion, including debt, with a discussed price above $75 per share. According to people familiar with the matter, the firms had agreed on the terms and lined up the necessary debt financing for

Description: Hologic (HOLX) shares caught investors’ attention this week after the company reported annual revenue growth of 5 percent along with a nearly 20 percent jump in net income. These results add context to its recent share price performance. See our latest analysis for Hologic. Hologic’s share price has regained some momentum lately, climbing over 9% in the past 90 days, even as its total shareholder return for the year sits at -14%. While recent financial results have reassured some investors,...